Research programme: PARP-1 inhibitors - Inotek/University of Pittsburgh

Drug Profile

Research programme: PARP-1 inhibitors - Inotek/University of Pittsburgh

Alternative Names: INH2BP; PARP-1 inhibitor

Latest Information Update: 13 Sep 2007

Price : $50

At a glance

  • Originator Inotek Pharmaceuticals; University of Pittsburgh
  • Class Neuroprotectants
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuroprotection

Most Recent Events

  • 04 Aug 2006 No development reported - Preclinical for Neuroprotection in USA (unspecified route)
  • 12 Sep 2003 This compound is still in active development
  • 11 Dec 2000 Preclinical development for Neuroprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top